Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
Exploration of Epigenetic Profiles in Circulating Tumor DNA to Identify Predictive Cancer Biomarkers
FY 2020-21
Summary
Current methods of tumor assessment through direct analysis of tumor tissue are invasive, painful, costly, and risky. Fortunately, much of the important information used for tumor assessment can be obtained from a cancer patient's blood, where material from dying tumor cells can be captured and analyzed. New non-invasive technologies using small amounts of blood are enabling extraction of tumor information for cancer diagnosis and monitoring response to treatment. In some instances, this information has also been used to select the optimal drug for treating a cancer patient in a process termed 'precision medicine'. One of the components extracted from cancer patient's blood is DNA from the tumor itself. Tumor-derived DNA fragments floating in the circulation hold a wealth of information that can be used to guide treatments. Specifically, new classes of drugs which act to change how genes in the tumor are controlled are moving into clinical settings. Unfortunately, tumor tissue is currently required to evaluate whether these drugs are having their intended effect in the tumor. Patterns of biological markers in the blood-derived DNA may hold information that will help guide clinicians on this new class of drugs, and evaluating these patterns is the goal of my project. In addition to guiding treatments, these markers may eventually be used to predict tumor growth without having to see the tumor itself in the patient. Our method, if successful, may be employed in the clinic for early cancer detection, monitoring of tumor recurrence, and prediction of patient tumor drug response on an individualized basis. Our method fills a crucial space in the health care industry for non-invasive evaluation of cancer patients.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
439356
Name
De Michino Steven D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Exploration of Epigenetic Profiles in Circulating Tumor DNA to Identify Predictive Cancer Biomarkers
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Cell-Free Chip-Seq; Circulating Tumor Dna; Histone Modifications; Liquid Biopsy; Personalized Medicine; Pharmacodynamic Biomarkers; Predictive Biomarkers
Abstract
Current methods of tumor assessment through direct analysis of tumor tissue are invasive, painful, costly, and risky. Fortunately, much of the important information used for tumor assessment can be obtained from a cancer patient's blood, where material from dying tumor cells can be captured and analyzed. New non-invasive technologies using small amounts of blood are enabling extraction of tumor information for cancer diagnosis and monitoring response to treatment. In some instances, this information has also been used to select the optimal drug for treating a cancer patient in a process termed 'precision medicine'. One of the components extracted from cancer patient's blood is DNA from the tumor itself. Tumor-derived DNA fragments floating in the circulation hold a wealth of information that can be used to guide treatments. Specifically, new classes of drugs which act to change how genes in the tumor are controlled are moving into clinical settings. Unfortunately, tumor tissue is currently required to evaluate whether these drugs are having their intended effect in the tumor. Patterns of biological markers in the blood-derived DNA may hold information that will help guide clinicians on this new class of drugs, and evaluating these patterns is the goal of my project. In addition to guiding treatments, these markers may eventually be used to predict tumor growth without having to see the tumor itself in the patient. Our method, if successful, may be employed in the clinic for early cancer detection, monitoring of tumor recurrence, and prediction of patient tumor drug response on an individualized basis. Our method fills a crucial space in the health care industry for non-invasive evaluation of cancer patients.
Competitiondate
202011
Approvedterm2
3 yrs 0 mth
Pinamesdelim
De Michino, Steven D
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~